• 100% radiographic partial response rate achieved in patients treated with NOX A12 + radiotherapy + bevacizumab. 83% of patients show durable mRANO responses.
• Of the 6 patients treated, 2 show a reduction in tumor size greater than 99%.
• 12-month survival data are expected in the second quarter of 2023.
• Organization of a webinar with the participation of an opinion leader on November 22, 2022, at 12:00 p.m. ET / 6:00 p.m. CET
Berlin, Germany, November 19, 2022, 01:30 CET – TME Pharma NV (Euronext Growth Paris: ALTME), a biotechnology company specializing in the development of novel therapies for the treatment of cancer by targeting the tumor microenvironment (MET), announces today today the presentation in a poster of its updated interim results of the expansion arm of the phase 1/2 clinical trial GLORIA evaluating NOX-A12 in combination with radiotherapy and bevacizumab (biosimilar of Avastin®) in cancer of the brain (glioblastoma) refractory to chemotherapy (unmethylated MGMT), at the annual meeting of the Society for Neuro-Oncology (SNO), held in Tampa, Florida, United States, from 16 to 20 November 2022.